Piper Sandler analyst Adam Maeder lowered the firm’s price target on Edwards Lifesciences to $68 from $83 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results, which delivered more-or-less an in-line print on both revenue and EPS. Piper was “encouraged” to see that U.S. TAVR came in above consensus, however, OUS TAVR was softer than anticipated and altogether Q3 WW TAVR missed Street forecasts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences price target lowered to $84 from $100 at JPMorgan
- Edwards Lifesciences price target lowered to $75 from $91 at Baird
- Edwards Lifesciences price target lowered to $85 from $90 at Mizuho
- Edwards Lifesciences price target lowered to $75 from $88 at Wells Fargo
- Edwards Lifesciences price target lowered to $85 from $94 at Citi